Aarti Drugs Limited saw its shares rise 1.34% to ₹402.00 following the announcement of its Q3 FY25 financial results. The company reported a 1.1% year-on-year (YoY) growth in consolidated net profit, which increased to ₹37.1 crore compared to ₹36.7 crore in the same quarter of the previous year. However, revenue declined 8.1% YoY to ₹556.6 crore from ₹605.9 crore, indicating ongoing margin pressures.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) fell to ₹61.8 crore, reflecting an 11.8% YoY decrease from ₹70.1 crore. The EBITDA margin contracted slightly to 11.1%, down from 11.6% in the previous year, highlighting the challenges in sustaining operational efficiencies amidst declining revenue.
The Board of Directors declared an interim dividend of ₹1 per equity share (10%) for FY25, with the record date set for February 4, 2025. This announcement boosted investor sentiment despite the company’s subdued operating performance.
Stock Performance: Aarti Drugs shares traded within a day range of ₹387.00 to ₹402.95. The company’s market capitalization stands at ₹36.64 billion, with an average trading volume of 219.81K shares on NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your research or consult a financial advisor before making investment decisions. Neither the author nor Business Upturn is liable for any losses arising from the use of this information.
